To study the efficacy of intradiscal autologous Platelet rich plasma injection in patients with lumbar disc disease

A quasi-experimental study on efficacy of intradiscal autologous platelet rich plasma injection in assessment of lower back pain and functional outcome in chronic lumbar disc prolapse-A pilot study - PLD

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058247

Enrollment

Registered

2023-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M511- Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathy

Interventions

Intervention1: INTRADISCAL AUTOLOGOUS PLATELET RICH PLASMA INJECTION: As the intervertebral disc is an avascular structure with minimal regenerative capacity, we are interest-ed in using autologous pl

Eligibility

Inclusion criteria

Inclusion criteria: 1)Age-18-50yrs 2)Refractory low back pain persisting for 3-12 weeks 3)lumbar disc protrusion or extrusion at single level 4)Maintained intervertebral disk height of at least 50% on MRI 5)Disc protrusion or extrusion seen on MRI corresponding to clinical findings 6)Decreased signal intensity of disc on MRI T2 imaging 7) Type 1 or Type 2 Modic changes of an end-plate on MRI

Exclusion criteria

Exclusion criteria: 1) Spinal dysmorphism 2) With neurological deficit 3) Sequestered disc fragments 4) previous surgical intervention for spine 5) Facet arthropathy 6) Sacroiliac joint pain 7) Traumatic spine injury 8) Known bleeding disorder or on anticoagulants or antiplatelet drugs 9) Pregnancy 10) Psychiatric condition 11) Peripheral neuropathy-diabetes with peripheral neuropathy, leprosy, syphilis 12) Tumors 13) Infective discitis

Design outcomes

Primary

Measure	Time frame
Change in VAS and FRI scores 3 weeks and 6 weeks post procedure as compared to baselineTimepoint: 1)At baseline 2)3 weeks post intervention 3)6 weeks post intervention	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactDr Prabu M

JIPMER

prabublue@gmail.com8220722782

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026